Joris B W Elbers
7PUBLICATIONS
59CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Jan 28, 2026
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.Lotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen
|Oct 08, 2025
Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.Sabine E Breukers, Joleen J H Traets, Stan W van Dijk
|Mar 22, 2024
Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors.Alberto Gil-Jimenez, Nick van Dijk, Joris L Vos
|Aug 24, 2023
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial.Joris L Vos, Bharat Burman, Swati Jain
|Aug 07, 2023
Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8+ T-cell and Activated Treg Compartment.Anne M van der Leun, Joleen J H Traets, Joris L Vos
|Jan 28, 2021
T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model.Emma H A Stahlie, Viola Franke, Charlotte L Zuur
Pageof 2
Frequent Collaborators
4 joint publications
Joris L Vos
3 joint publications
John B A G Haanen
2 joint publications
Christian U Blank
2 joint publications
Daniela S Thommen
2 joint publications
Michel W Wouters
2 joint publications
Ton N Schumacher
2 joint publications
Alexander C J van Akkooi
2 joint publications
Xiaohang Qiao
1 joint publications
Viola Franke
1 joint publications
Bart A Van de Wiel
